Table 2.

Baseline depression and quality-of-life measures

Variables, Median (IQR) or N (%)SertralinePlacebo
Responders, n=31Nonresponders, n=66Responders, n=24Nonresponders, n=72
QIDS-C16
 Total score15.0 (12.0–17.0)13.0 (12.0–15.0)13.0 (11.5–15.0)14.0 (12.0–16.0)
 Somatic subscale total9.0 (8.0–10.0)8.0 (7.0–9.0)9.0 (7.0–9.0)9.0 (8.0–10.0)
 Sleep3.0 (2.0–3.0)3.0 (2.0–3.0)3.0 (2.0–3.0)3.0 (2.0–3.0)
 Appetite/weight2.0 (1.0–2.0)2.0 (1.0–2.0)1.0 (1.0–2.0)2.0 (1.0–2.0)
 Concentration2.0 (1.0–2.0)1.0 (1.0–2.0)1.0 (1.0–2.0)1.0 (1.0–2.0)
 Fatigue2.0 (1.0–2.0)2.0 (1.0–2.0)2.0 (2.0–2.0)2.0 (2.0–2.0)
 Psychomotor agitation/retardation1.0 (1.0–2.0)1.0 (1.0–1.0)1.0 (1.0–1.5)1.0 (1.0–2.0)
 Nonsomatic subscale total6.0 (4.0–7.0)5.0 (4.0–6.0)5.0 (5.0–4.0)5.0 (4.0–7.0)
 Sadness2.0 (1.0–2.0)2.0 (1.0–2.0)1.0 (1.0–2.0)2.0 (1.0–2.0)
 Self-perception2.0 (1.0–2.0)1.0 (1.0–2.0)a1.0 (0.0–2.0)1.0 (1.0–2.0)
 Suicide0.0 (0.0–1.0)0.0 (0.0–1.0)0.0 (0.0–1.0)0.0 (0.0–1.0)
 Anhedonia2.0 (2.0–3.0)2.0 (2.0–2.0)2.0 (2.0–3.0)2.0 (2.0–3.0)
KDQOL-SF 1.3 subscales
 Kidney disease component
  Burden of kidney disease50.0 (25.0–68.8)40.6 (25.0–62.5)50.0 (37.5–65.6)37.5 (18.8–56.3)b
  Symptoms/problems68.2 (59.1–77.3)67.4 (56.8–77.3)68.2 (55.1–85.2)68.2 (56.8–75.0)
  Effects of kidney disease62.5 (43.8–81.2)65.6 (46.9–81.2)73.4 (60.9–90.6)65.6 (43.8–78.1)b
  Work status0.0 (0.0–50.0)0.0 (0.0–50.0)0.0 (0.0–50.0)0.0 (0.0–0.0)
  Cognitive function66.7 (46.7–80.0)66.7 (53.3–80.0)76.7 (60.0–96.7)60.0 (46.7–80.0)b
  Quality of social interaction60.0 (53.3–73.3)66.7 (53.3–80.0)60.0 (46.7–76.7)53.3 (46.7–66.7)
  Sexual function43.8 (25.0–75.0)62.5 (25.0–87.5)87.5 (25.0–87.5)62.5 (37.5–100.0)
  Sleep50.0 (40.0–67.5)51.3 (40.0–62.5)60.0 (45.0–72.5)50.0 (37.5–60.0)
  Social support66.7 (50.0–83.3)66.7 (50.0–83.3)50.0 (33.3–83.3)66.7 (33.3–66.7)
  Patient satisfaction66.7 (58.3–83.3)66.7 (50.0–83.3)66.7 (66.7–100.0)66.7 (50.0–83.3)
 Physical functioning component
  Physical functioning37.5 (20.0–60.0)35.0 (15.0–55.0)30.0 (20.0–67.5)25.0 (15.0–50.0)
  Role limits, physical0.0 (0.0–25.0)0.0 (0.0–0.0)0.0 (0.0–62.5)0.0 (0.0–0.0)b
  Pain35.0 (22.5–67.5)45.0 (22.5–67.5)45.0 (22.5–80.0)35.0 (22.5–55.0)
  General health30.0 (15.0–45.0)35.0 (20.0–45.0)32.5 (22.5–50.0)30.0 (15.0–35.0)
 Mental functioning component
  Emotional wellbeing60.0 (44.0–72.0)58.0 (44.0–68.0)62.5 (50.0–74.0)52.0 (44.0–60.0)b
  Role limits, emotional33.3 (0.0–66.7)0.0 (0.0–66.7)33.3 (0.0–83.3)0.0 (0.0–33.3)
  Social function50.0 (25.0–75.0)50.0 (37.5–62.5)50.0 (37.5–87.5)37.5 (25.0–50.0)b
  Energy/fatigue35.0 (20.0–50.0)35.0 (20.0–46.7)37.5 (25.0–55.0)25.0 (15.0–40.0)b
  Overall health50.0 (30.0–60.0)50.0 (30.0–50.0)50.0 (35.0–50.0)50.0 (30.0–50.0)
  SF-36 physical composite29.1 (26.7–35.2)27.9 (24.0–35.3)25.7 (23.8–45.0)26.8 (23.2–34.9)
  SF-36 mental composite42.4 (32.2–47.0)38.6 (34.5–46.5)39.9 (36.3–50.5)37.9 (29.2–42.8)b
  SF-12 physical composite29.1 (26.3–39.9)29.1 (25.7–36.2)29.2 (27.3–39.7)28.5 (23.9–34.9)
  SF-12 mental composite40.5 (33.6–48.0)37.1 (33.0–43.9)39.9 (34.8–49.8)37.7 (31.5–41.5)
  • IQR, interquartile range; QIDS-C16, clinician-rated 16-item Quick Inventory of Depressive Symptomatology scale; KDQOL-SF 1.3, Kidney Disease Quality of Life Survey Short Form, Version 1.3; SF-36, Short Form 36 Health Survey; SF-12, Short Form 12.

  • a P<0.05 for responders versus nonresponders in the sertraline group.

  • b P<0.05 for responders versus nonresponders in the placebo group.